CLRB - Cellectar Biosciences - Stock Forecast

Coverage Stock analysts Price Targets & Ratings Chart Insider Trading

CLRB is currently covered by 2 analysts with an average price target of $13.44. This is a potential upside of $8.94 (198.67%) from yesterday's end of day stock price of $4.5.

Cellectar Biosciences's activity chart (see below) currently has 1 price targets and 13 ratings on display. The stock rating distribution of CLRB is 90% BUY and 10% HOLD.

Stock Analyst Price Targets - Review

Analysts average stock forecasts to be materialized ratio is 50% with an average time for these price targets to be met of 225.5 days.

Highest price target for CLRB is $4, Lowest price target is $4.

Most recent stock forecast was given by JONATHAN ASCHOFF from ROTH on 28-Mar-2024. First documented stock forecast 02-May-2019.

Best performing analysts who are covering CLRB - Cellectar Biosciences:

Jonathan Aschoff Swayampakula Ramakanth

Currently out of the existing stock ratings of CLRB, 9 are a BUY (90%), 1 are a HOLD (10%).

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Buy

$20

1 years 4 months 22 days ago
(28-Mar-2024)

0/2 (0%)

$15.76 (371.70%)

Buy

$4

$2.61 (187.77%)

2 years 9 months 15 days ago
(04-Nov-2022)

1/1 (100%)

$2.11 (111.64%)

451

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What is CLRB (Cellectar Biosciences) average time for price targets to be met?

On average it took 225.5 days on average for the stock forecasts to be realized with a an average price target met ratio 50

Which analyst has the current highest performing score on CLRB (Cellectar Biosciences) with a proven track record?

JONATHAN ASCHOFF

Which analyst has the current lower performing score on CLRB (Cellectar Biosciences) with a proven track record?

SWAYAMPAKULA RAMAKANTH

Which analyst has the most public recommendations on CLRB (Cellectar Biosciences)?

Jonathan Aschoff has 2 price targets and 3 ratings on CLRB

Which analyst is the currently most bullish on CLRB (Cellectar Biosciences)?

Swayampakula Ramakanth with highest potential upside - $2.61

Which analyst is the currently most reserved on CLRB (Cellectar Biosciences)?

Jonathan Aschoff with lowest potential downside - -$0

Cellectar Biosciences in the News

Cellectar Biosciences to Report Second Quarter Financial Results and Host a Conference Call on Thursday, August 14, 2025

FLORHAM PARK, N.J., Aug. 07, 2025 (GLOBE NEWSWIRE) — Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced that the Company will report financial results for the second quarter ended June 30, 2025, and provide a corporate update...

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?